All Trials

A Pilot, Rapid Sequencing of First Line Cabozantinib, Ipilimumab and Nivolumab, and Lenvatinib and Everolimus in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated metastatic or unresectable clear cell RCC (ECOG 0–1; stable treated brain mets allowed) receive a rapid sequence: cabozantinib lead-in (multi-target TKI inhibiting MET/VEGFR/AXL/RET) → ipilimumab (CTLA-4) plus nivolumab (PD-1) → response-adapted maintenance with nivolumab or switch at progression to cabozantinib or lenvatinib (VEGFR/FGFR TKI) plus everolimus (mTOR inhibitor). Excludes prior systemic therapy for advanced disease and significant autoimmune, cardiovascular, bleeding, or GI risks.

ClinicalTrials.gov ID: NCT05188118

A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic clear cell, translocation, or chromophobe RCC or urothelial carcinoma with measurable disease and prior progression on PD-1/PD-L1 (plus prior VEGFR TKI for RCC and chemo or ADC for UC) receive autologous cytokine-induced memory-like NK cells after lymphodepletion, supported by low-dose IL-2. CIML NK cells are ex vivo cytokine-activated NK cells designed to enhance innate antitumor cytotoxicity, cytokine production, and persistence; treated, stable brain metastases allowed.

ClinicalTrials.gov ID: NCT06318871

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed metastatic RCC (clear or non–clear cell, primary tumor in place) who achieve disease control after ~12 weeks of first-line ICI-based therapy (nivolumab/ipilimumab; or pembrolizumab+axitinib; or avelumab+axitinib) are randomized to continue systemic therapy alone versus cytoreductive nephrectomy followed by the same regimen. ICIs target PD-1/PD-L1 and CTLA-4 to restore antitumor immunity; axitinib is a VEGFR TKI.

ClinicalTrials.gov ID: NCT04510597

GU-187: Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic RCC (clear or non–clear cell) or progressive well-differentiated NETs receive cabozantinib using a finer titration schema (starting 40 mg daily with 10 mg adjustments; max 60 mg), with frontline RCC patients in one cohort also receiving standard-dose nivolumab (PD‑1 inhibitor). Excludes prior cabozantinib and significant cardiovascular/GI risks; NET cohort may continue stable somatostatin analogs.

ClinicalTrials.gov ID: NCT05263050

Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Treatment-naive adults with advanced/metastatic clear cell RCC are assigned by tumor RNAseq biologic clusters (1/2 vs 4/5) to either ipilimumab plus nivolumab (CTLA-4 + PD-1 blockade) or nivolumab plus cabozantinib (PD-1 inhibitor with VEGF/MET/AXL-targeting TKI). Includes patients with controlled brain mets; key exclusions address cardiovascular risk, bleeding/proteinuria, and factors affecting cabozantinib safety or absorption.

ClinicalTrials.gov ID: NCT05361720

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with previously untreated metastatic clear cell RCC (ECOG 0–1) eligible for cytoreductive nephrectomy, giving neoadjuvant nivolumab (PD‑1 inhibitor) plus cabozantinib (VEGFR/MET/AXL TKI) for ~12 weeks, then nephrectomy with cabozantinib held 14–21 days pre-op and therapy resumed if benefiting. Aims to increase complete responses and assess tumor shrinkage, survival, and surgical outcomes.

ClinicalTrials.gov ID: NCT04322955

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresected, metastatic or node-positive RCC (IMDC intermediate/poor risk) receiving standard first-line immunotherapy (IO-IO or IO-VEGF regimens) are randomized to immunotherapy alone versus the same therapy plus stereotactic ablative radiotherapy (SABR) to the intact primary kidney tumor. Regimens may include nivolumab + ipilimumab (PD-1 + CTLA-4), pembrolizumab or nivolumab combinations with VEGF/VEGFR TKIs (axitinib, lenvatinib, cabozantinib), or avelumab + axitinib.

ClinicalTrials.gov ID: NCT05327686

A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with functioning kidney transplants and unresectable or metastatic cutaneous melanoma (non-uveal), cSCC, BCC, or Merkel cell carcinoma receive nivolumab (PD‑1 inhibitor) plus ipilimumab (CTLA‑4 inhibitor) with concurrent sirolimus (mTOR inhibitor) and prednisone, followed by nivolumab maintenance. Designed to balance antitumor activity with graft preservation; prior PD-(L)1 exposure allowed, with re-induction permitted at progression.

ClinicalTrials.gov ID: NCT05896839

A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with multiple myeloma and significant renal impairment (eGFR <45) receive cyclophosphamide plus low-dose total body irradiation for lymphodepletion instead of fludarabine, followed by ciltacabtagene autoleucel (BCMA-directed CAR T with dual BCMA-binding domains). The study assesses safety/feasibility of this TBI-based approach and its impact on CAR T expansion and antimyeloma activity.

ClinicalTrials.gov ID: NCT06623630

Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Newly diagnosed multiple myeloma patients with significant renal impairment (CrCl <60 mL/min and/or dialysis) receive four 28-day cycles of subcutaneous daratumumab-hyaluronidase (anti‑CD38) plus bortezomib, cyclophosphamide, and dexamethasone, with outcomes focused on depth of hematologic response and renal recovery. Planned enrichment for approximately 50% African American participants; post-induction therapy follows standard practice (ASCT if eligible or additional Dara-CyBorD, then maintenance with lenalidomide plus SC daratumumab).

ClinicalTrials.gov ID: NCT06142396